Tango Therapeutics Inc (TNGX NASDAQ) stock market data APIs
$7.6389
-0.29(-3.8%)
as of September 17, 2025
Try our APIs with
free plan!
Tango Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Prev. Close
7.6389
Open
7.3527
High
7.9934
Low
7.2396
52 wk Range
1.03-8.58
Market Cap
848 M
Shares Outstanding
111 M
Revenue
24 296 K
EPS
-0.35
Beta
1.646
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tango Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tango Therapeutics Inc data using free add-ons & libraries
Get Tango Therapeutics Inc Fundamental Data
Tango Therapeutics Inc Fundamental data includes:
- Net Revenue: 24 296 K
- EBITDA: -154 796 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tango Therapeutics Inc News
New
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock?
Tango Therapeutics, Inc. (TNGX) shares ended the last trading session 7.8% higher at $7.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the sess...
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...
Summit draws Neutral view on risk/reward setup as Piper initiates biotech cancer names
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Piper Sandler launched the coverage of a raft of cancer-focused biotechs with bullish views on Monday while issuing a Neutral recommendation on ...
Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
